Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | FUT4 | P22083 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7570296 | 0.80 | KDM4E (0.41) | TDP1KDM4EMAPTHSD17B10ALDH1A1 | |
| Acetamide SCHEMBL7546231 | 0.78 | LMNA (0.36) | TDP1KDM4EMAPTHSD17B10ALDH1A1 | |
| Glycine SCHEMBL5386703 | 0.75 | BACE1 (0.44) | GLRA1SLC6A9OR51E2TDP1KDM4E | |
| Glycine SCHEMBL5077295 | 0.73 | FFAR4 (0.44) | GLRA1SLC6A9OR51E2CA1CA2 | |
| Gallic Acid SCHEMBL4126178 | 0.72 | KDM4E (0.74) | GLRA1SLC6A9OR51E2TDP1KDM4E | |
| Phloroglucinol SCHEMBL28571198 | 0.69 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2LMNACA12 | |
| Glycine SCHEMBL30338272 | 0.68 | GLRA1 (0.91) | GLRA1SLC6A9OR51E2KDM4EALDH1A1 | |
| Glycine SCHEMBL30338545 | 0.68 | GLRA1 (0.91) | GLRA1SLC6A9OR51E2KDM4EALDH1A1 | |
| Glycine SCHEMBL29906512 | 0.68 | — | — | |
| Glycine SCHEMBL252376 | 0.66 | GLRA1 (0.62) | GLRA1SLC6A9OR51E2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107952065-A | Include the Insulin Aspart for being substituted anionic compound | 阿道恰公司 | 2018-04-24 | — | — | CN | claimed |
| CN-104902922-B | Fast acting insulin formulations comprising substituted anionic compounds | 阿道恰公司 | 2017-12-12 | — | — | CN | claimed |
| US-8883716-B2 | Method for treating damaged tissue of the CNS | MEDTRONIC, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120143272-A1 | METHOD FOR TREATING DAMAGED TISSUE OF THE CNS | MEDTRONIC, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20050123526-A1 | Administration of growth factors for neurogenesis and gliagenesis | MEDTRONIC INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1536790-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | AstraZeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014370-A2 | OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| JP-2003335666-A | MEDICAMENT FOR SPECIFICALLY INHIBITING NEUROCYTE IN HYPERSTIMULATION | KATO NOBUO | 2003-11-25 | — | — | JP | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |